G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Paolo Strati,Hagop M. Kantarjian,Farhad Ravandi,Aziz Nazha,Gautam Borthakur,Naval Daver,Tapan M. Kadia,Zeev Estrov,Guillermo Garcia-Manero,Marina Konopleva,Trivikram Rajkhowa,Menda Durand,Michael Andreeff,Mark J. Levis,Jorge E. Cortes +14 more
TL;DR: The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high‐risk MDS and patients with FLT3 mutations but not previously exposed to otherFLT3 inhibitors and patients not previously transplanted derived the greatest benefit.
Journal ArticleDOI
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Elias Jabbour,Hagop M. Kantarjian,Susan O'Brien,Jenny Shan,Alfonso Quintás-Cardama,Stefan Faderl,Guillermo Garcia-Manero,Farhad Ravandi,Mary Beth Rios,Jorge E. Cortes +9 more
TL;DR: It is concluded that second tyrosine kinase inhibitors induced higher rates of CCyR and MMR than imatinib, and remains a major determinant of chronic myeloid leukemia outcome regardless of whether MMR is achieved or not.
Journal ArticleDOI
Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia
Apostolia Maria Tsimberidou,William G. Wierda,William Plunkett,Razelle Kurzrock,Susan O'Brien,Sijin Wen,Alessandra Ferrajoli,Farhad Ravandi-Kashani,Guillermo Garcia-Manero,Zeev Estrov,Thomas J. Kipps,Jennifer R. Brown,Albert Fiorentino,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: The OFAR regimen is highly active in RS and has activity in fludarabine-refractory patients with CLL, and warrants further investigation in the treatment of these disorders.
Journal ArticleDOI
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Elias Jabbour,Hagop M. Kantarjian,Dan Jones,Jenny Shan,Susan O'Brien,Neeli Reddy,William G. Wierda,Stefan Faderl,Guillermo Garcia-Manero,Srdan Verstovsek,Mary Beth Rios,Jorge E. Cortes +11 more
TL;DR: Imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetics failure and a previous cytogenetic response to standard-dose imatinib, which is well tolerated and long-lasting.
Journal ArticleDOI
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Kiyomi Morita,Kiyomi Morita,Hagop M. Kantarjian,Feng Wang,Yuanqing Yan,Carlos Bueso-Ramos,Koji Sasaki,Ghayas C. Issa,Sa Wang,Jeffrey L. Jorgensen,Xingzhi Song,Jianhua Zhang,Samantha Tippen,Rebecca Thornton,Marcus Coyle,Latasha Little,Curtis Gumbs,Naveen Pemmaraju,Naval Daver,Courtney D. DiNardo,Marina Konopleva,Michael Andreeff,Farhad Ravandi,Jorge E. Cortes,Tapan M. Kadia,Elias J. Jabbour,Guillermo Garcia-Manero,Keyur P. Patel,P. Andrew Futreal,Koichi Takahashi +29 more
TL;DR: Clearance of somatic mutation at CR, particularly in nonpreleukemic genes, was associated with significantly better survival and less risk of relapse in patients with acute myeloid leukemia.